Zencurix Submits Securities Registration Statement for KOSDAQ Technology Special Listing

[Asia Economy Reporter Kum Boryeong] GenCurix has submitted a securities registration statement to pursue a KOSDAQ technical special listing.

GenCurix announced on the 28th that it submitted the securities registration statement to the Financial Services Commission yesterday and has started the public offering process for listing on KOSDAQ.

The number of shares to be offered in this listing is 1 million shares. The desired offering price band is 22,700 to 26,100 KRW. The total offering amount is approximately 22.7 billion KRW based on the lower end of the offering price. The company plans to finalize the offering price through demand forecasting on the 10th and 11th of next month and conduct subscription on the 15th and 16th. The goal is to enter KOSDAQ by the end of next month. Mirae Asset Daewoo is the lead underwriter.

GenCurix, a molecular diagnostics specialist company, developed the first breast cancer prognosis diagnostic kit in Korea. Based on cancer diagnostic technology, it is achieving results in prognosis diagnostics and companion diagnostics. In March, it obtained export approval from the Ministry of Food and Drug Safety for its COVID-19 diagnostic kit and acquired European medical device certification (CE), and has been proceeding with exports. It is discussing export contracts with companies and government agencies in about 20 countries.

Joo Sangrae, CEO of GenCurix, said, "Our technology has already been recognized for excellence, having received A and A grades from two evaluation agencies, and we are confident in significant external growth this year through expanding sales of molecular diagnostic products and COVID-19 diagnostic kits. We will grow into a global diagnostic company by leveraging the best domestic research talent pool and an excellent product portfolio."